A Phase 1/2 interventional study of Durvalumab and Lenalidomide in Lymphoma and Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Celgene. Completed at 66 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Lymphoma by Bristol-Myers Squibb — 2 open to participants now, 5 under way, 1 of them phase 3. Lymphoma · Bristol-Myers Squibb.
Among the 42 studies in Lymphoma by Bristol-Myers Squibb, this one is the 12th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2016, is one of 6 in phase 1/2, and was the 23rd registered.
3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.
Browse Lymphoma studies →2 of the 42 studies in Lymphoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, France, Germany
Ages 18+
Turning Point Therapeutics, Inc. · Sites in United States, Australia, Canada and 8 more countries
Ages up to 25
By country, each count listing its studies:
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 17 · Phase 3 5
First in 2006; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 43 across 2,320 interventional studies indexed under Lymphoma.
Median enrollment 74 across the 39 interventional studies, 151 across the 3 observational. Of the 36 that completed or were terminated, 17 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
1 of the studies in Lymphoma by Bristol-Myers Squibb that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06356129Phase 3CelgeneStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | 2027-08-09 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies in Lymphoma by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to determine the recommended phase 2 dose (RP2D), and the safety, and efficacy of durvalumab as monotherapy and when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab at the RP2D in adults with lymphoma or chronic lymphocytic leukemia (CLL).
The study was to consist of 3 parts: dose-finding, dose-confirmation, and dose-expansion. In this study, 4 treatment arms were to be investigated:
The study was to start with 3 dose-finding cohorts (Arms A, B, and C) and 1 dose-confirmation cohort (Arm D) in parallel. All treatment arms were to be open for enrollment at study start except in the US, where Arm D was to enroll depending on the availability of treatment slots and following the completion of assessment of responses from the combination therapy arms. For Arms A and C, prior to enrolling participants to receive all 3 drugs, the doublet combinations were to be evaluated. Once the doublet combinations were deemed tolerable, the eventual triplet combinations were to be tested.
On 05 September 2017, the US FDA issued a Partial Clinical Hold on the study Arm A. Following this Partial Clinical Hold no more participants were enrolled into study Arm A. Participants already enrolled and treated in Arm A who were receiving clinical benefit, based on the discretion of the investigator, could continue study treatment after being reconsented. Arm B and C completed dose confirmation. The dose expansion part of the study was not opened.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Subject who received any prior monoclonal antibodies against programmed cell death-1 () or programmed cell death ligand-1 (PD-L1) and/or any prior:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to Arm A will receive: * Durvalumab 1500 mg intravenous (IV) infusion on Day 1 of Cycles 1 through 13 (ie, 12 months) and * Lenalidomide orally at assigned dose levels (10 mg, 15 mg or 20 mg) once daily on Days 1 to 21 of: * Cycles 1 through 13 in indolent non-Hodgkin's lymphoma (NHL) or * All cycles of treatment period until disease progression, unacceptable toxicity, or discontinuation for any other reason in aggressive NHL * Rituximab 375 mg/m² IV infusion every week in Cycle 1 (Days 2, 8, 15, 22) and on Day 1 of Cycles 2 through 5. All treatment cycles were 28 days.
Drug: Durvalumab · Drug: Lenalidomide · Drug: Rituximab
Participants assigned to Arm B will receive: * Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13 * Ibrutinib orally at assigned dose levels (280 mg, 420 mg, or 560 mg) once daily until disease progression, unacceptable toxicity or discontinuation for any other reason. All treatment cycles were 28 days.
Drug: Durvalumab · Drug: Ibrutinib
Participants assigned to Arm C will receive: * Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13 * Rituximab 375 mg/m² IV infusion on Day 2 of Cycles 1 through 6 (for CLL the rituximab dose will be 375 mg/m² Cycle 1 first dose and 500 mg/m² for each subsequent dose) * Bendamustine IV infusion at assigned dose levels (70 mg/m² or 90 mg/m²) on Days 1 and 2 of Cycles 1 through 6. All treatment cycles were 28 days.
Drug: Durvalumab · Drug: Rituximab · Drug: Bendamustine
Participants assigned to Arm D will receive durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13. All treatment cycles were 28 days.
Drug: Durvalumab
Administered as an IV infusion (250 mL) over approximately 1 hour in duration
Also known as: MEDI4736, IMFINZI®
Administered orally
Also known as: Revlimid®
Administered by intravenous infusion
Also known as: Rituxan®, MabThera®
Administered orally
Also known as: Imbruvica®
Administered as a 30-minute intravenous infusion
Also known as: Treanda®, Bendeka®, Levact®
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
Dose limiting toxicities were evaluated during the DLT evaluation period for participants in the dose finding cohorts. The severity grading was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03. A DLT is defined as below: Hematologic DLT • Grade 4 neutropenia observed for greater than 5 days duration • Grade 3 neutropenia associated with fever (≥ 38.5 °C) of any duration • Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding, or any requirement for platelets transfusion • Grade 4 anemia, unexplained by underlying disease • Any other grade 4 hematologic toxicity that does not resolve to participant's pretreatment baseline level within 72 hours. Non-Hematologic DLT • Any non-hematological toxicity ≥ Grade 3 except for alopecia and nausea controlled by medical management • Any treatment interruption greater than 2 weeks due to adverse event.
Time frame: Cycle 1 (28 days)
Number of Participants With Treatment-emergent Adverse Events
Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) occurring or worsening on or after the first dose of any study treatment (durvalumab, lenalidomide, ibrutinib, bendamustine or rituximab) and within 90 days after last dose of durvalumab or 28 days after the last dose of other study drugs, whichever was later, as well as those serious adverse events made known to the investigator at any time thereafter that were suspected of being related to study treatment. The intensity of AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. For all other AEs not described in the CTCAE criteria, the intensity was assessed by the investigator as mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), or death (Grade 5).
Time frame: From first dose of any study drug to 90 days after last dose of durvalumab or 28 days after last dose of other study drugs, up to the data cut-off date of 6 March 2019. Maximum time on treatment was 55.4 weeks for DUR and 130 weeks for other study drugs.
Overall Response Rate (ORR) During Durvalumab Treatment
For lymphoma participants, response evaluation was based on International Working Group (IWG) response criteria for malignant lymphoma (the Lugano Classification). Overall response rate is defined as the percent of participants with best response of complete response (CR) or partial response (PR). For chronic lymphocytic leukemia participants, response evaluation was based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines for diagnosis and treatment of CLL. The ORR is defined as the percent of participants with best response of CR, complete response with incomplete marrow recovery (CRi), nodular partial response (nPR), PR, or partial response with lymphocytosis (PRL).
Time frame: Up to 13 cycles (12 months)
Overall Response Rate During the Entire Study
For lymphoma participants, response evaluation was based on International Working Group (IWG) response criteria for malignant lymphoma (the Lugano Classification) (Cheson, 2014). Overall response rate is defined as the percent of participants with best response of complete response (CR) or partial response (PR). For chronic lymphocytic leukemia participants, response evaluation was based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines for diagnosis and treatment of CLL. The ORR is defined as the percentage of participants with best response of CR, complete response with incomplete marrow recovery (CRi), nodular partial response (nPR), PR, or partial response with lymphocytosis (PRL).
Time frame: From first dose of any study drug to the end of follow-up, up to the data cutoff date of March 6, 2019; median (minimum, maximum) time on study was 16.7 (0.9, 32.9) months.
Time to First Response
Time to response was calculated as the time from first dose of study drug to the first response date (CR or PR for lymphoma participants and CR, CRi, nPR, PR, or PRL for CLL participants).
Time frame: From first dose of any study drug to the end of follow-up, up to the data cutoff date of March 6, 2019; median (minimum, maximum) time on study was 16.7 (0.9, 32.9) months.
Kaplan-Meier Estimate of Duration of Response
Duration of response is defined for responders only as the time from the first documented response (CR or PR for lymphoma participants or CR, CRi, nPR, PR, or PRL for CLL participants) to disease progression or death (from any cause). For participants with response but no progression, or death, duration of response was censored at the last date that the participant was known to be progression-free.
Time frame: From first dose of any study drug to the end of follow-up, up to the data cutoff date of March 6, 2019; median (minimum, maximum) time on study was 16.7 (0.9, 32.9) months.
Kaplan-Meier Estimate of Progression-free Survival (PFS)
Progression-free survival was calculated as the time from first dose of study drug to the first documented progression or death (from any cause) during the entire efficacy evaluation period. For participants with no progression or death, PFS was censored at the last assessment date the participant was known to be progression-free.
Time frame: From first dose of any study drug to the end of follow-up, up to the data cutoff date of March 6, 2019; median (minimum, maximum) time on study was 16.7 (0.9, 32.9) months.
Maximum Observed Plasma Concentration (Cmax) of Durvalumab
Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Time to Maximum Plasma Concentration (Tmax) of Durvalumab
Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Durvalumab
Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Durvalumab
Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Terminal Elimination Phase Half-Life (t½) of Durvalumab
Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Clearance (CL) of Durvalumab
Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Volume of Distribution (Vz) of Durvalumab
Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Maximum Observed Plasma Concentration (Cmax) of Lenalidomide
Time frame: Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose, and Cycle 1 Day 15 at pre-dose, 1, 2, and 4 hours post-dose.
Time to Maximum Observed Plasma Concentration (Tmax) of Lenalidomide
Time frame: Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose, and Cycle 1 Day 15 at pre-dose, 1, 2, and 4 hours post-dose.
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Lenalidomide
Time frame: Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
Time frame: Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose, and Cycle 1 Day 15 at pre-dose, 1, 2, and 4 hours post-dose.
Time to Maximum Observed Plasma Concentration (Tmax) of Ibrutinib
Time frame: Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose, and Cycle 1 Day 15 at pre-dose, 1, 2, and 4 hours post-dose.
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Ibrutinib
Time frame: Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose
Change From Baseline in Soluble Programmed Cell Death Ligand-1 (sPD-L1) Concentration
Change from baseline in sPD-L1 could not be calculated as all post-baseline samples were below the lower limit of quantification (\<15.60 pg/mL).
Time frame: Baseline (Cycle 1 Day 1 predose) and Day 1 of Cycles 2 to 13
| Milestone | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 8 | 3 | 4 | 3 | 1 | 4 | 5 | 10 | 10 | 10 | 10 | 5 | 5 | 10 | 2 | 5 | 5 |
| Participants who entered follow-up period after completing/discontinuing study treatment | 3 | 3 | 6 | 3 | 2 | 2 | 0 | 4 | 4 | 4 | 5 | 9 | 9 | 4 | 1 | 5 | 0 | 3 | 2 |
| Completed | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 6 | 4 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Not completed | 3 | 2 | 7 | 3 | 3 | 3 | 1 | 3 | 5 | 4 | 6 | 6 | 9 | 4 | 5 | 10 | 2 | 5 | 4 |
| Withdrew: Adverse event | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Progressive disease | 2 | 1 | 3 | 1 | 2 | 3 | 0 | 3 | 3 | 2 | 2 | 2 | 8 | 1 | 4 | 7 | 2 | 3 | 4 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other reasons | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
Dose limiting toxicities were evaluated during the DLT evaluation period for participants in the dose finding cohorts. The severity grading was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03. A DLT is defined as below: Hematologic DLT • Grade 4 neutropenia observed for greater than 5 days duration • Grade 3 neutropenia associated with fever (≥ 38.5 °C) of any duration • Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding, or any requirement for platelets transfusion • Grade 4 anemia, unexplained by underlying disease • Any other grade 4 hematologic toxicity that does not resolve to participant's pretreatment baseline level within 72 hours. Non-Hematologic DLT • Any non-hematological toxicity ≥ Grade 3 except for alopecia and nausea controlled by medical management • Any treatment interruption greater than 2 weeks due to adverse event.
| Participants | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) | 0 | 3 | 1 | 0 | 0 | 0 | — | 0 | 1 |
Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) occurring or worsening on or after the first dose of any study treatment (durvalumab, lenalidomide, ibrutinib, bendamustine or rituximab) and within 90 days after last dose of durvalumab or 28 days after the last dose of other study drugs, whichever was later, as well as those serious adverse events made known to the investigator at any time thereafter that were suspected of being related to study treatment. The intensity of AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. For all other AEs not described in the CTCAE criteria, the intensity was assessed by the investigator as mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), or death (Grade 5).
| Participants | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | 3 | 3 | 8 | 3 | 4 | 3 | 1 | 4 | 5 | 10 | 10 | 10 | 9 | 5 | 5 | 9 | 2 | 5 | 5 |
| TEAE Related to Any Study Drug | 3 | 3 | 8 | 3 | 4 | 3 | 0 | 4 | 5 | 10 | 9 | 10 | 9 | 5 | 4 | 3 | 0 | 3 | 2 |
| CTCAE Grade 3-4 TEAE | 1 | 3 | 7 | 2 | 3 | 2 | 1 | 3 | 4 | 8 | 10 | 6 | 9 | 5 | 4 | 7 | 1 | 4 | 3 |
| CTCAE Grade 3-4 TEAE Related to Any Study Drug | 1 | 3 | 7 | 1 | 1 | 2 | 0 | 2 | 2 | 7 | 6 | 5 | 7 | 3 | 3 | 2 | 0 | 1 | 1 |
| CTCAE Grade 5 TEAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 4 | 0 | 0 | 0 |
| CTCAE Grade 5 TEAE Related to Any Study Drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Serious TEAE | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 3 | 6 | 7 | 5 | 5 | 2 | 4 | 7 | 0 | 3 | 2 |
| Serious TEAE Related to Any Study Drug | 1 | 2 | 3 | 1 | 0 | 1 | 0 | 0 | 1 | 2 | 3 | 3 | 3 | 1 | 3 | 1 | 0 | 0 | 0 |
| TEAE Leading to Discontinuation of Any Study Drug | 1 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 2 | 1 | 0 | 0 | 1 | 0 |
| TEAE Leading to Dose Modifications of Study Drug | 1 | 3 | 3 | 3 | 4 | 3 | 1 | 4 | 4 | 8 | 9 | 7 | 4 | 3 | 2 | 0 | 0 | 3 | 3 |
For lymphoma participants, response evaluation was based on International Working Group (IWG) response criteria for malignant lymphoma (the Lugano Classification). Overall response rate is defined as the percent of participants with best response of complete response (CR) or partial response (PR). For chronic lymphocytic leukemia participants, response evaluation was based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines for diagnosis and treatment of CLL. The ORR is defined as the percent of participants with best response of CR, complete response with incomplete marrow recovery (CRi), nodular partial response (nPR), PR, or partial response with lymphocytosis (PRL).
| percentage of participants | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) During Durvalumab Treatment | 33.3 (0.8 to 90.6) | 66.7 (9.4 to 99.2) | 80.0 (28.4 to 99.5) | 66.7 (9.4 to 99.2) | 75.0 (19.4 to 99.4) | 33.3 (0.8 to 90.6) | — | 50.0 (6.8 to 93.2) | 0 (NA to NA) | 88.9 (51.8 to 99.7) | 60.0 (26.2 to 87.8) | 88.9 (51.8 to 99.7) | 30.0 (6.7 to 65.2) | 50.0 (6.8 to 93.2) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 20.0 (0.5 to 71.6) |
For lymphoma participants, response evaluation was based on International Working Group (IWG) response criteria for malignant lymphoma (the Lugano Classification) (Cheson, 2014). Overall response rate is defined as the percent of participants with best response of complete response (CR) or partial response (PR). For chronic lymphocytic leukemia participants, response evaluation was based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines for diagnosis and treatment of CLL. The ORR is defined as the percentage of participants with best response of CR, complete response with incomplete marrow recovery (CRi), nodular partial response (nPR), PR, or partial response with lymphocytosis (PRL).
| percentage of participants | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Response Rate During the Entire Study | 66.7 (9.4 to 99.2) | 66.7 (9.4 to 99.2) | 80.0 (28.4 to 99.5) | 66.7 (9.4 to 99.2) | 75.0 (19.4 to 99.4) | 33.3 (0.8 to 90.6) | — | 50.0 (6.8 to 93.2) | 0 (NA to NA) | 100.0 (66.4 to 100.0) | 70.0 (34.8 to 93.3) | 88.9 (51.8 to 99.7) | 30.0 (6.7 to 65.2) | 50.0 (6.8 to 93.2) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 20.0 (0.5 to 71.6) |
Time to response was calculated as the time from first dose of study drug to the first response date (CR or PR for lymphoma participants and CR, CRi, nPR, PR, or PRL for CLL participants).
| weeks | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to First Response | 70.85 (12.1 to 129.6) | 12.60 (12.1 to 13.1) | 18.20 (11.3 to 36.1) | 11.85 (11.4 to 12.3) | 13.40 (12.4 to 52.9) | 13.00 (13.0 to 13.0) | — | 13.10 (12.1 to 14.1) | — | 12.10 (10.9 to 72.9) | 12.10 (6.6 to 26.4) | 12.35 (10.3 to 15.3) | 12.00 (8.7 to 12.1) | 12.10 (12.1 to 12.1) | — | — | — | — | 13.10 (13.1 to 13.1) |
Duration of response is defined for responders only as the time from the first documented response (CR or PR for lymphoma participants or CR, CRi, nPR, PR, or PRL for CLL participants) to disease progression or death (from any cause). For participants with response but no progression, or death, duration of response was censored at the last date that the participant was known to be progression-free.
| weeks | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kaplan-Meier Estimate of Duration of Response | 10.14 (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 29.29 (NA to NA) | — | NA (NA to NA) | — | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 24.14 (9.14 to 26.14) | NA (NA to NA) | — | — | — | — | 11.14 (NA to NA) |
Progression-free survival was calculated as the time from first dose of study drug to the first documented progression or death (from any cause) during the entire efficacy evaluation period. For participants with no progression or death, PFS was censored at the last assessment date the participant was known to be progression-free.
| months | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kaplan-Meier Estimate of Progression-free Survival (PFS) | 8.41 (5.09 to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 28.71 (4.50 to NA) | 9.69 (1.64 to 12.68) | 1.25 (NA to NA) | 3.82 (1.25 to NA) | 2.48 (0.49 to 5.91) | NA (NA to NA) | NA (NA to NA) | 14.65 (5.75 to 14.65) | 2.06 (0.76 to 8.28) | NA (NA to NA) | 1.68 (0.69 to 4.63) | 1.17 (0.26 to 3.19) | 2.76 (2.50 to 3.02) | 2.33 (0.79 to 10.02) | 2.66 (2.56 to 5.98) |
| μg/L | Arm A: Durvalumab + Lenalidomide ± Rituximab | Arm B: Durvalumab + Ibrutinib | Arm C: Durvalumab + Bendamustine ± Rituximab | Arm D: Durvalumab Monotherapy |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Durvalumab | 420264.066 ± 22.7 | 361906.229 ± 30.1 | 331572.478 ± 33.4 | 392663.668 ± 41.1 |
| days | Arm A: Durvalumab + Lenalidomide ± Rituximab | Arm B: Durvalumab + Ibrutinib | Arm C: Durvalumab + Bendamustine ± Rituximab | Arm D: Durvalumab Monotherapy |
|---|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Durvalumab | 0.0510 (0.042 to 1.035) | 0.0479 (0.041 to 1.061) | 0.0510 (0.042 to 6.788) | 0.0420 (0.038 to 1.986) |
| days*μg/L | Arm A: Durvalumab + Lenalidomide ± Rituximab | Arm B: Durvalumab + Ibrutinib | Arm C: Durvalumab + Bendamustine ± Rituximab | Arm D: Durvalumab Monotherapy |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Durvalumab | 3120149.759 ± 29.5 | 3225869.344 ± 31.9 | 2670168.397 ± 46.7 | 3053060.746 ± 37.8 |
| days*μg/L | Arm A: Durvalumab + Lenalidomide ± Rituximab | Arm B: Durvalumab + Ibrutinib | Arm C: Durvalumab + Bendamustine ± Rituximab | Arm D: Durvalumab Monotherapy |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Durvalumab | 4867431.378 ± 23.3 | 5818262.846 ± 42.1 | 4762968.345 ± 71.0 | 5593532.553 ± 53.0 |
| days | Arm A: Durvalumab + Lenalidomide ± Rituximab | Arm B: Durvalumab + Ibrutinib | Arm C: Durvalumab + Bendamustine ± Rituximab | Arm D: Durvalumab Monotherapy |
|---|---|---|---|---|
| Terminal Elimination Phase Half-Life (t½) of Durvalumab | 11.596 ± 46.6 | 17.344 ± 47.3 | 16.327 ± 57.4 | 15.399 ± 53.5 |
| L/day | Arm A: Durvalumab + Lenalidomide ± Rituximab | Arm B: Durvalumab + Ibrutinib | Arm C: Durvalumab + Bendamustine ± Rituximab | Arm D: Durvalumab Monotherapy |
|---|---|---|---|---|
| Clearance (CL) of Durvalumab | 0.3082 ± 23.3 | 0.2578 ± 42.1 | 0.3149 ± 71.0 | 0.2682 ± 53.0 |
| liters | Arm A: Durvalumab + Lenalidomide ± Rituximab | Arm B: Durvalumab + Ibrutinib | Arm C: Durvalumab + Bendamustine ± Rituximab | Arm D: Durvalumab Monotherapy |
|---|---|---|---|---|
| Volume of Distribution (Vz) of Durvalumab | 5.155 ± 41.9 | 6.451 ± 38.3 | 7.418 ± 33.7 | 5.957 ± 33.0 |
| ng/mL | Arm A: Lenalidomide 10 mg | Arm A: Lenalidomide 20 mg |
|---|---|---|
| Cycle 1 Day 1 | 141.881 ± 22.0 | 309.917 ± 6.9 |
| Cycle 1 Day 15 | 107.635 ± 40.9 | 174.090 |
| hours | Arm A: Lenalidomide 10 mg | Arm A: Lenalidomide 20 mg |
|---|---|---|
| Cycle 1 Day 1 | 1.9500 (1.000 to 3.917) | 1.1667 (1.000 to 1.433) |
| Cycle 1 Day 15 | 3.0333 (1.233 to 4.000) | 1.000 (1.000 to 1.000) |
| h*ng/mL | Arm A: Lenalidomide 10 mg | Arm A: Lenalidomide 20 mg |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Lenalidomide | 789.297 ± 84.3 | 805.299 ± 56.0 |
| ng/mL | Arm B: Ibrutinib 420 mg | Arm B: Ibrutinib 560 mg |
|---|---|---|
| Cycle 1 Day 1 | 129.704 ± 98.0 | 67.728 ± 197.9 |
| Cycle 1 Day 15 | 86.840 ± 136.9 | 72.436 ± 166.3 |
| hours | Arm B: Ibrutinib 420 mg | Arm B: Ibrutinib 560 mg |
|---|---|---|
| Cycle 1 Day 1 | 2.000 (0.000 to 4.367) | 1.9333 (0.933 to 3.917) |
| Cycle 1 Day 15 | 1.8833 (1.000 to 4.000) | 2.000 (1.000 to 4.083) |
| h*ng/mL | Arm B: Ibrutinib 420 mg | Arm B: Ibrutinib 560 mg |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Ibrutinib | 586.396 ± 117.2 | 436.855 ± 246.5 |
Change from baseline in sPD-L1 could not be calculated as all post-baseline samples were below the lower limit of quantification (\<15.60 pg/mL).
No measurements were reported for this outcome.
TEAEs defined as AEs occurring or worsening on or after first dose of any study treatment (durvalumab, lenalidomide, ibrutinib, bendamustine or rituximab) and within 90 days after last dose of durvalumab or 28 days after the last dose of other study drugs, whichever was later, as well as those serious adverse events made known to the investigator at any time thereafter that were suspected of being related to study treatment. Intensity of AEs graded according to the NCI CTCAE V. 4.03. For all other AEs not described in the CTCAE criteria, the intensity was assessed by investigator as mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), or death (Grade 5). This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date (assessments made until August 21, 2022).
| Participants | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | 3 | 3 | 8 | 3 | 4 | 3 | 1 | 4 | 5 | 10 | 10 | 10 | 9 | 5 | 5 | 9 | 2 | 5 | 5 |
| TEAE Related to Any Study Drug | 3 | 3 | 8 | 3 | 4 | 3 | 0 | 4 | 5 | 10 | 9 | 10 | 9 | 5 | 4 | 3 | 0 | 3 | 2 |
| CTCAE Grade 3-4 TEAE | 1 | 3 | 7 | 2 | 4 | 2 | 1 | 3 | 4 | 9 | 10 | 6 | 9 | 5 | 4 | 7 | 1 | 4 | 3 |
| CTCAE Grade 3-4 TEAE Related to Any Study Drug | 1 | 3 | 7 | 1 | 1 | 2 | 0 | 2 | 2 | 8 | 6 | 5 | 7 | 3 | 3 | 2 | 0 | 1 | 1 |
| CTCAE Grade 5 TEAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 4 | 0 | 0 | 0 |
| CTCAE Grade 5 TEAE Related to Any Study Drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Serious TEAE | 1 | 2 | 4 | 2 | 3 | 2 | 1 | 1 | 3 | 6 | 7 | 5 | 5 | 2 | 4 | 7 | 0 | 3 | 2 |
| Serious TEAE Related to Any Study Drug | 1 | 2 | 3 | 1 | 0 | 1 | 0 | 0 | 1 | 3 | 3 | 3 | 3 | 1 | 3 | 1 | 0 | 0 | 0 |
| TEAE Leading to Discontinuation of Any Study Drug | 1 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 2 | 1 | 0 | 0 | 1 | 0 |
| TEAE Leading to Dose Modifications of Study Drug | 1 | 3 | 5 | 3 | 4 | 3 | 1 | 4 | 4 | 9 | 9 | 7 | 4 | 3 | 2 | 0 | 0 | 3 | 3 |
Collected over All-cause mortality was assessed from the participants first dose to their study completion (up to approximately 75 months). SAEs and Other AEs were assessed from first dose to 90 days from the last dose of durvalumab or 28 days from the last dose of any other study treatment [ie, lenalidomide, ibrutinib, rituximab, bendamustine, or involved field radiation (IFRT) therapy], whichever occurs later (up to approximately 75 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1, Arm A: DUR 1500 mg + LEN 20 mg | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | 2/8 (25%) | 4/8 (50%) | 8/8 (100%) |
| Part 1, Arm B: DUR 1500 mg + IBR 420 mg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 1, Arm B: DUR 1500 mg + IBR 560 mg | 3/4 (75%) | 3/4 (75%) | 4/4 (100%) |
| Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | 3/4 (75%) | 1/4 (25%) | 4/4 (100%) |
| Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | 4/5 (80%) | 3/5 (60%) | 5/5 (100%) |
| Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | 1/10 (10%) | 6/10 (60%) | 10/10 (100%) |
| Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | 2/10 (20%) | 7/10 (70%) | 10/10 (100%) |
| Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | 0/10 (0%) | 5/10 (50%) | 10/10 (100%) |
| Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | 9/10 (90%) | 5/10 (50%) | 9/10 (90%) |
| Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | 2/5 (40%) | 2/5 (40%) | 5/5 (100%) |
| Part 2, Arm D FL: DUR 1500 mg | 4/5 (80%) | 4/5 (80%) | 5/5 (100%) |
| Part 2, Arm D DLBCL: DUR 1500 mg | 9/10 (90%) | 8/10 (80%) | 10/10 (100%) |
| Part 2, Arm D CLL/SLL: DUR 1500 mg | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Part 2, Arm D MCL: DUR 1500 mg | 4/5 (80%) | 4/5 (80%) | 5/5 (100%) |
| Part 2, Arm D HL: DUR 1500 mg | 4/5 (80%) | 2/5 (40%) | 5/5 (100%) |
| Event | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SepsisInfections and infestations | 0/3 | 1/3 | 1/8 | 0/3 | 0/4 | 0/3 | 1/1 | 0/4 | 0/5 | 0/10 | 0/10 | 0/10 | 0/10 | 1/5 | 1/5 | 0/10 | 0/2 | 0/5 | 1/5 |
| Acute kidney injuryRenal and urinary disorders | 0/3 | 1/3 | 0/8 | 0/3 | 1/4 | 0/3 | 1/1 | 0/4 | 0/5 | 1/10 | 0/10 | 0/10 | 0/10 | 0/5 | 0/5 | 0/10 | 0/2 | 0/5 | 0/5 |
| General physical health deteriorationGeneral disorders | 0/3 | 0/3 | 0/8 | 0/3 | 0/4 | 0/3 | 0/1 | 0/4 | 1/5 | 0/10 | 0/10 | 0/10 | 0/10 | 0/5 | 0/5 | 2/10 | 0/2 | 2/5 | 1/5 |
| PyrexiaGeneral disorders | 0/3 | 1/3 | 1/8 | 0/3 | 0/4 | 1/3 | 0/1 | 0/4 | 0/5 | 0/10 | 1/10 | 0/10 | 1/10 | 0/5 | 1/5 | 0/10 | 0/2 | 0/5 | 2/5 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/3 | 0/3 | 1/8 | 0/3 | 0/4 | 0/3 | 0/1 | 0/4 | 0/5 | 1/10 | 0/10 | 1/10 | 0/10 | 0/5 | 0/5 | 0/10 | 0/2 | 0/5 | 0/5 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 1/3 | 0/8 | 0/3 | 0/4 | 0/3 | 0/1 | 0/4 | 0/5 | 0/10 | 0/10 | 0/10 | 0/10 | 0/5 | 0/5 | 0/10 | 0/2 | 0/5 | 0/5 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 1/3 | 0/8 | 0/3 | 0/4 | 0/3 | 0/1 | 0/4 | 1/5 | 0/10 | 0/10 | 0/10 | 0/10 | 0/5 | 0/5 | 0/10 | 0/2 | 0/5 | 0/5 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/3 | 0/8 | 0/3 | 0/4 | 1/3 | 0/1 | 0/4 | 0/5 | 0/10 | 0/10 | 0/10 | 0/10 | 0/5 | 0/5 | 0/10 | 0/2 | 1/5 | 0/5 |
| Rectal haemorrhageGastrointestinal disorders | 0/3 | 0/3 | 0/8 | 0/3 | 0/4 | 1/3 | 0/1 | 0/4 | 0/5 | 0/10 | 0/10 | 0/10 | 0/10 | 0/5 | 0/5 | 0/10 | 0/2 | 0/5 | 0/5 |
| Generalised oedemaGeneral disorders | 0/3 | 0/3 | 0/8 | 0/3 | 0/4 | 1/3 | 0/1 | 0/4 | 0/5 | 0/10 | 0/10 | 0/10 | 0/10 | 0/5 | 1/5 | 0/10 | 0/2 | 0/5 | 0/5 |
| Event | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/3 | 0/3 | 3/8 | 0/3 | 2/4 | 0/3 | 0/1 | 1/4 | 3/5 | 0/10 | 3/10 | 1/10 | 5/10 | 1/5 | 1/5 | 2/10 | 2/2 | 1/5 | 2/5 |
| NeutropeniaBlood and lymphatic system disorders | 1/3 | 1/3 | 4/8 | 1/3 | 1/4 | 1/3 | 0/1 | 2/4 | 1/5 | 4/10 | 3/10 | 6/10 | 3/10 | 1/5 | 0/5 | 3/10 | 2/2 | 3/5 | 1/5 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 1/3 | 2/8 | 0/3 | 2/4 | 0/3 | 0/1 | 1/4 | 2/5 | 3/10 | 3/10 | 2/10 | 6/10 | 1/5 | 1/5 | 4/10 | 2/2 | 3/5 | 1/5 |
| ConstipationGastrointestinal disorders | 3/3 | 1/3 | 4/8 | 0/3 | 3/4 | 1/3 | 0/1 | 1/4 | 0/5 | 1/10 | 2/10 | 3/10 | 1/10 | 1/5 | 2/5 | 0/10 | 0/2 | 0/5 | 0/5 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 1/3 | 2/8 | 3/3 | 2/4 | 1/3 | 0/1 | 1/4 | 1/5 | 5/10 | 5/10 | 2/10 | 1/10 | 1/5 | 1/5 | 0/10 | 0/2 | 2/5 | 3/5 |
| AstheniaGeneral disorders | 1/3 | 0/3 | 0/8 | 1/3 | 1/4 | 1/3 | 0/1 | 0/4 | 0/5 | 0/10 | 2/10 | 1/10 | 3/10 | 0/5 | 1/5 | 2/10 | 2/2 | 3/5 | 2/5 |
| Skin infectionInfections and infestations | 0/3 | 0/3 | 0/8 | 0/3 | 0/4 | 0/3 | 1/1 | 0/4 | 0/5 | 0/10 | 0/10 | 1/10 | 0/10 | 1/5 | 0/5 | 0/10 | 0/2 | 0/5 | 0/5 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/3 | 3/3 | 0/8 | 0/3 | 1/4 | 0/3 | 0/1 | 0/4 | 0/5 | 2/10 | 0/10 | 0/10 | 0/10 | 0/5 | 0/5 | 0/10 | 0/2 | 0/5 | 0/5 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/3 | 0/3 | 0/8 | 0/3 | 0/4 | 0/3 | 1/1 | 0/4 | 0/5 | 0/10 | 0/10 | 0/10 | 0/10 | 0/5 | 0/5 | 0/10 | 0/2 | 0/5 | 0/5 |
| PyrexiaGeneral disorders | 1/3 | 1/3 | 2/8 | 0/3 | 1/4 | 1/3 | 0/1 | 1/4 | 3/5 | 3/10 | 2/10 | 3/10 | 4/10 | 1/5 | 2/5 | 6/10 | 1/2 | 4/5 | 2/5 |
| Age, Continuous(years) | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 71.0 (50 to 78) | 66.0 (52 to 75) | 77.0 (53 to 80) | 58.0 (54 to 74) | 68.0 (57 to 81) | 79.0 (76 to 80) | 70.0 (70 to 70) | 68.0 (52 to 78) | 38.0 (21 to 77) | 68.0 (55 to 73) | 73.5 (54 to 84) | 64.5 (45 to 75) | 60.0 (46 to 71) | 68.0 (53 to 79) | 52.0 (39 to 71) | 61.5 (22 to 76) | 62.0 (55 to 69) | 77.0 (69 to 80) | 51.0 (34 to 65) | 67.0 (21 to 84) |
| Age, Customized(Participants) | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 65 Years | 1 | 1 | 2 | 2 | 1 | 0 | 0 | 1 | 3 | 4 | 2 | 5 | 7 | 2 | 3 | 5 | 1 | 0 | 4 | 44 |
| ≥ 65 Years | 2 | 2 | 6 | 1 | 3 | 3 | 1 | 3 | 2 | 6 | 8 | 5 | 3 | 3 | 2 | 5 | 1 | 5 | 1 | 62 |
| Sex: Female, Male(Participants) | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 1 | 3 | 3 | 1 | 3 | 4 | 2 | 2 | 4 | 1 | 2 | 2 | 35 |
| Male | 2 | 3 | 6 | 3 | 2 | 1 | 1 | 3 | 2 | 7 | 9 | 7 | 6 | 3 | 3 | 6 | 1 | 3 | 3 | 71 |
| Ethnicity (NIH/OMB)(Participants) | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 2 | 2 | 7 | 2 | 3 | 1 | 1 | 3 | 3 | 5 | 7 | 6 | 8 | 3 | 2 | 9 | 2 | 5 | 5 | 76 |
| Unknown or Not Reported | 1 | 1 | 1 | 1 | 0 | 2 | 0 | 1 | 2 | 5 | 3 | 4 | 2 | 1 | 3 | 1 | 0 | 0 | 0 | 28 |
| Race/Ethnicity, Customized(Participants) | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 2 | 2 | 3 | 2 | 4 | 0 | 1 | 0 | 4 | 5 | 6 | 4 | 4 | 4 | 2 | 9 | 2 | 4 | 5 | 63 |
| Asian | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 13 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Not Collected or Reported | 1 | 1 | 1 | 1 | 0 | 3 | 0 | 1 | 0 | 5 | 3 | 4 | 2 | 1 | 3 | 1 | 0 | 0 | 0 | 27 |
| Histology(Participants) | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Follicular lymphoma | 1 | 3 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 10 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 23 |
| Diffuse large B-cell lymphoma | 2 | 0 | 4 | 0 | 0 | 2 | 1 | 3 | 5 | 0 | 0 | 0 | 10 | 0 | 0 | 10 | 0 | 0 | 0 | 37 |
| Marginal zone lymphoma | 0 | 0 | 2 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Transformed follicular lymphoma | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Mantle cell lymphoma | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 17 |
| CLL / SLL | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 5 | 0 | 0 | 2 | 0 | 0 | 18 |
| Hodgkin lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 |
| Eastern Cooperative Oncology Group ECOG) Performance Status(Participants) | Part 1, Arm A: DUR 1500 mg + LEN 20 mg | Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m² | Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m² | Part 1, Arm B: DUR 1500 mg + IBR 420 mg | Part 1, Arm B: DUR 1500 mg + IBR 560 mg | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² | Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² | Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg | Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg | Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² | Part 2, Arm D FL: DUR 1500 mg | Part 2, Arm D DLBCL: DUR 1500 mg | Part 2, Arm D CLL/SLL: DUR 1500 mg | Part 2, Arm D MCL: DUR 1500 mg | Part 2, Arm D HL: DUR 1500 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 - Fully Active | 0 | 2 | 2 | 0 | 1 | 1 | 0 | 3 | 2 | 8 | 6 | 6 | 7 | 0 | 2 | 3 | 1 | 4 | 5 | 53 |
| 1 - Restricted but ambulatory | 3 | 1 | 4 | 3 | 3 | 2 | 0 | 0 | 2 | 2 | 3 | 3 | 1 | 4 | 2 | 4 | 1 | 1 | 0 | 39 |
| 2 - Ambulatory but unable to work | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 2 | 0 | 0 | 0 | 13 |
| 3 - Limited self-care | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Mar 2019, 33 months.
Results were first posted in Mar 2020, 1 year after primary completion.
Of 66 industry-sponsored phase 1/2 interventional studies under Lymphoma, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 87. This study's 33 months is below that.
Counting every sponsor, half of 143 studies reached it within 74 months; a quarter within 48 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Durvalumab